Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2012.45.2011 on January 21 2014

Journal of Clinical Oncology, Vol 32, No 6 (February 20), 2014: pp. 579-586
© 2014 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diaz, L. A.
Right arrow Articles by Bardelli, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diaz, L. A., Jr
Right arrow Articles by Bardelli, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Delicious   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

BIOLOGY OF NEOPLASIA

Liquid Biopsies: Genotyping Circulating Tumor DNA

Luis A. Diaz, Jr, Alberto Bardelli

Luis A. Diaz Jr, Swim Across America Laboratory and Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD; and Alberto Bardelli, Institute for Cancer Research and Treatment at Candiolo, University of Torino, Candiolo, and the Fondazione Italiana per la Ricerca sul Cancro Institute of Molecular Oncology, Milan, Italy.

Corresponding author: Alberto Bardelli, PhD, Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, Department of Oncology, University of Torino, Medical School, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy; e-mail: a.bardelli{at}unito.it.

Genotyping tumor tissue in search of somatic genetic alterations for actionable information has become routine practice in clinical oncology. Although these sequence alterations are highly informative, sampling tumor tissue has significant inherent limitations; tumor tissue is a single snapshot in time, is subject to selection bias resulting from tumor heterogeneity, and can be difficult to obtain. Cell-free fragments of DNA are shed into the bloodstream by cells undergoing apoptosis or necrosis, and the load of circulating cell-free DNA (cfDNA) correlates with tumor staging and prognosis. Moreover, recent advances in the sensitivity and accuracy of DNA analysis have allowed for genotyping of cfDNA for somatic genomic alterations found in tumors. The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time as well as serving as a liquid biopsy that can be used for a variety of clinical and investigational applications not previously possible.

Supported by the European Union Seventh Framework Programme of the Colon Therapy Research Consortium (Grant No. 259015); by the Associazione Italiana per la Ricerca sul Cancro (AIRC) Investigator Grant No. 12812; by AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille, Project No. 9970; by Fondazione Piemontese per la Ricerca sul Cancro 5 per mille 2010 Ministero della Salute; Ministero dell'Istruzione, dell'Università e della Ricerca (Progetti di Ricerca di Interesse Nazionale), and by Swim Across America.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
E. Van Cutsem, A. Cervantes, R. Adam, A. Sobrero, J. H. Van Krieken, D. Aderka, E. Aranda Aguilar, A. Bardelli, A. Benson, G. Bodoky, et al.
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Ann. Onc., August 1, 2016; 27(8): 1386 - 1422.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. I. Pentsova, R. H. Shah, J. Tang, A. Boire, D. You, S. Briggs, A. Omuro, X. Lin, M. Fleisher, C. Grommes, et al.
Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid
J. Clin. Oncol., July 10, 2016; 34(20): 2404 - 2415.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Kawaguchi, Y. Koh, M. Ando, N. Ito, S. Takeo, H. Adachi, T. Tagawa, S. Kakegawa, M. Yamashita, K. Kataoka, et al.
Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study
J. Clin. Oncol., July 1, 2016; 34(19): 2247 - 2257.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Roschewski, L. M. Staudt, and W. H. Wilson
Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma
Blood, June 23, 2016; 127(25): 3127 - 3132.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
A. Stahlberg, P. M. Krzyzanowski, J. B. Jackson, M. Egyud, L. Stein, and T. E. Godfrey
Simple, multiplexed, PCR-based barcoding of DNA enables sensitive mutation detection in liquid biopsies using sequencing
Nucleic Acids Res., June 20, 2016; 44(11): e105 - e105.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Jovelet, E. Ileana, M.-C. Le Deley, N. Motte, S. Rosellini, A. Romero, C. Lefebvre, M. Pedrero, N. Pata-Merci, N. Droin, et al.
Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
Clin. Cancer Res., June 15, 2016; 22(12): 2960 - 2968.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
S. Faillot and G. Assie
ENDOCRINE TUMOURS: The genomics of adrenocortical tumors
Eur. J. Endocrinol., June 1, 2016; 174(6): R249 - R265.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Karlovich, J. W. Goldman, J.-M. Sun, E. Mann, L. V. Sequist, K. Konopa, W. Wen, P. Angenendt, L. Horn, D. Spigel, et al.
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Clin. Cancer Res., May 15, 2016; 22(10): 2386 - 2395.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
C. Trejo-Becerril, E. Perez-Cardenas, B. Gutierrez-Diaz, D. De La Cruz-Sigüenza, L. Taja-Chayeb, M. Gonzalez-Ballesteros, P. Garcia-Lopez, J. Chanona, and A. Duenas-Gonzalez
Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model
Integr Cancer Ther, May 4, 2016; (2016) 1534735416631102v1.
[Abstract] [PDF]


Home page
Ann OncolHome page
M. Jamal-Hanjani, G. A. Wilson, S. Horswell, R. Mitter, O. Sakarya, T. Constantin, R. Salari, E. Kirkizlar, S. Sigurjonsson, R. Pelham, et al.
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
Ann. Onc., May 1, 2016; 27(5): 862 - 867.
[Abstract] [Full Text] [PDF]


Home page
Cancer DiscoveryHome page
C. Alix-Panabieres and K. Pantel
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Cancer Discovery, May 1, 2016; 6(5): 479 - 491.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
Z. Szallasi
Another surprising role for exosomes? Improving next-generation sequencing-based cancer diagnostics in liquid biopsies
Ann. Onc., April 1, 2016; 27(4): 557 - 558.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Lehmann-Werman, D. Neiman, H. Zemmour, J. Moss, J. Magenheim, A. Vaknin-Dembinsky, S. Rubertsson, B. Nellgard, K. Blennow, H. Zetterberg, et al.
Identification of tissue-specific cell death using methylation patterns of circulating DNA
PNAS, March 29, 2016; 113(13): E1826 - E1834.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Wang, A. Bahreini, R. Gyanchandani, P. C. Lucas, R. J. Hartmaier, R. J. Watters, A. R. Jonnalagadda, H. E. Trejo Bittar, A. Berg, R. L. Hamilton, et al.
Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Clin. Cancer Res., March 1, 2016; 22(5): 1130 - 1137.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Ocana, L. Diez-Gonzalez, D. C. Garcia-Olmo, A. J. Templeton, F. Vera-Badillo, M. Jose Escribano, G. Serrano-Heras, V. Corrales-Sanchez, B. Seruga, F. Andres-Pretel, et al.
Circulating DNA and Survival in Solid Tumors
Cancer Epidemiol. Biomarkers Prev., February 1, 2016; 25(2): 399 - 406.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Santiago-Walker, R. Gagnon, J. Mazumdar, M. Casey, G. V. Long, D. Schadendorf, K. Flaherty, R. Kefford, A. Hauschild, P. Hwu, et al.
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
Clin. Cancer Res., February 1, 2016; 22(3): 567 - 574.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
D. Torchinsky and Y. Ebenstein
Sizing femtogram amounts of dsDNA by single-molecule counting
Nucleic Acids Res., January 29, 2016; 44(2): e17 - e17.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
B. T. Li, A. Drilon, M. L. Johnson, M. Hsu, C. S. Sima, C. McGinn, H. Sugita, M. G. Kris, and C. G. Azzoli
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers
Ann. Onc., January 1, 2016; 27(1): 154 - 159.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. J. Xu, J. F. Dorsey, R. Amaravadi, G. Karakousis, C. B. Simone II, X. Xu, W. Xu, E. L. Carpenter, L. Schuchter, and G. D. Kao
Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma
Oncologist, January 1, 2016; 21(1): 84 - 94.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
T. R. Pisanic II, P. Athamanolap, W. Poh, C. Chen, A. Hulbert, M. V. Brock, J. G. Herman, and T.-H. Wang
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies
Nucleic Acids Res., December 15, 2015; 43(22): e154 - e154.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. W. Jones
Precision Oncology Framework for Investigation of Exercise As Treatment for Cancer
J. Clin. Oncol., December 10, 2015; 33(35): 4134 - 4137.
[Full Text] [PDF]


Home page
Eur Respir JHome page
J. Remon, J. Gorham, B. Besse, and J.-P. Sculier
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients?
Eur. Respir. J., December 1, 2015; 46(6): 1548 - 1550.
[Abstract] [Full Text] [PDF]


Home page
Cancer DiscoveryHome page
E. L. Kwak, L. G. Ahronian, G. Siravegna, B. Mussolin, J. T. Godfrey, J. W. Clark, L. S. Blaszkowsky, D. P. Ryan, J. K. Lennerz, A. J. Iafrate, et al.
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
Cancer Discovery, December 1, 2015; 5(12): 1271 - 1281.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Ignatiadis, M. Lee, and S. S. Jeffrey
Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility
Clin. Cancer Res., November 1, 2015; 21(21): 4786 - 4800.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. L. Siu, B. A. Conley, S. Boerner, and P. M. LoRusso
Next-Generation Sequencing to Guide Clinical Trials
Clin. Cancer Res., October 15, 2015; 21(20): 4536 - 4544.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Frenel, S. Carreira, J. Goodall, D. Roda, R. Perez-Lopez, N. Tunariu, R. Riisnaes, S. Miranda, I. Figueiredo, D. Nava-Rodrigues, et al.
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
Clin. Cancer Res., October 15, 2015; 21(20): 4586 - 4596.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. P. Bruce, K. Yip, S. V. Bratman, E. Ito, and F.-F. Liu
Nasopharyngeal Cancer: Molecular Landscape
J. Clin. Oncol., October 10, 2015; 33(29): 3346 - 3355.
[Abstract] [Full Text] [PDF]


Home page
Clinical ChemistryHome page
M. B. Freidin, D. V. Freydina, M. Leung, A. Montero Fernandez, A. G. Nicholson, and E. Lim
Circulating Tumor DNA Outperforms Circulating Tumor Cells for KRAS Mutation Detection in Thoracic Malignancies
Clin. Chem., October 1, 2015; 61(10): 1299 - 1304.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. W. Murray and N. Miller
Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance
Mol. Cancer Ther., September 1, 2015; 14(9): 1975 - 1984.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C. Montagut, G. Siravegna, and A. Bardelli
Liquid biopsies to evaluate early therapeutic response in colorectal cancer
Ann. Onc., August 1, 2015; 26(8): 1525 - 1527.
[Full Text] [PDF]


Home page
EMBO Mol Med.Home page
A. W. Wyatt and M. E. Gleave
Targeting the adaptive molecular landscape of castration-resistant prostate cancer
EMBO Mol Med., July 1, 2015; 7(7): 878 - 894.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
E. Bohers, P. J. Viailly, S. Dubois, P. Bertrand, C. Maingonnat, S. Mareschal, P. Ruminy, J.-M. Picquenot, C. Bastard, F. Desmots, et al.
Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis
Haematologica, July 1, 2015; 100(7): e280 - e284.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Mouliere and N. Rosenfeld
Circulating tumor-derived DNA is shorter than somatic DNA in plasma
PNAS, March 17, 2015; 112(11): 3178 - 3179.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Jamal-Hanjani, S. A. Quezada, J. Larkin, and C. Swanton
Translational Implications of Tumor Heterogeneity
Clin. Cancer Res., March 15, 2015; 21(6): 1258 - 1266.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
J. M. Kros, D. M. Mustafa, L. J. M. Dekker, P. A. E. Sillevis Smitt, T. M. Luider, and P.-P. Zheng
Circulating glioma biomarkers
Neuro Oncology, March 1, 2015; 17(3): 343 - 360.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Kawaguchi, M. Ando, and A. Kubo
Reply to G. Spitzer and M.A. Socinski, F. Zhou et al, and B. Biswas
J. Clin. Oncol., February 10, 2015; 33(5): 526 - 527.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. Qiu, J. Wang, Y. Xu, X. Ding, M. Li, F. Jiang, L. Xu, and R. Yin
Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non-Small Cell Lung Cancer: A Meta-analysis
Cancer Epidemiol. Biomarkers Prev., January 1, 2015; 24(1): 206 - 212.
[Abstract] [Full Text] [PDF]


Home page
Clinical ChemistryHome page
E. Schutz, M. R. Akbari, J. Beck, H. Urnovitz, W. W. Zhang, K. Bornemann-Kolatzki, W. M. Mitchell, R. K. Nam, and S. A. Narod
Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer
Clin. Chem., January 1, 2015; 61(1): 239 - 248.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C. Yoo, M.- H. Ryu, Y. S. Na, B.- Y. Ryoo, S. R. Park, and Y.- K. Kang
Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors
Ann. Onc., November 1, 2014; 25(11): 2272 - 2277.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prev ResHome page
M.-A. D. Smit, E. M. Jaffee, and E. R. Lutz
Cancer Immunoprevention--The Next Frontier
Cancer Prevention Research, November 1, 2014; 7(11): 1072 - 1080.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Rothe, J.- F. Laes, D. Lambrechts, D. Smeets, D. Vincent, M. Maetens, D. Fumagalli, S. Michiels, S. Drisis, C. Moerman, et al.
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer
Ann. Onc., October 1, 2014; 25(10): 1959 - 1965.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
T. N. Beck, A. J. Chikwem, N. R. Solanki, and E. A. Golemis
Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer
Physiol Genomics, October 1, 2014; 46(19): 699 - 724.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J. J. Luke, G. R. Oxnard, C. P. Paweletz, D. R. Camidge, J. V. Heymach, D. B. Solit, B. E. Johnson, and for the Cell Free DNA Working Group
Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies
J Natl Cancer Inst, August 1, 2014; 106(8): dju214 - dju214.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
W. D. Figg and D. R. Newell
Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine
Clin. Cancer Res., May 15, 2014; 20(10): 2525 - 2529.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. F. Gainor, D. L. Longo, and B. A. Chabner
Pharmacodynamic Biomarkers: Falling Short of the Mark?
Clin. Cancer Res., May 15, 2014; 20(10): 2587 - 2594.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2014 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online